



**Louisiana Department of Health
Health Plan Advisory 17-8
May 2, 2017**

Single Preferred Drug List (PDL) for Selected Therapeutic Classes

The Louisiana Department of Health (LDH) is establishing a single Preferred Drug List (PDL) for selected therapeutic classes, and Managed Care Organizations (MCO) shall implement it effective Oct. 1, 2017.

LDH shall determine the selected therapeutic classes and drugs included. MCO Pharmacy Directors shall work with LDH to establish prior authorization criteria applicable to drugs included in the Single PDL for selected therapeutic classes. The criteria will apply uniformly to all MCOs and fee for service.

MCOs shall not enter into rebate agreements with manufacturers of drugs included in the Single PDL for selected therapeutic classes. Any current rebate agreements for drugs included in the Single PDL for selected therapeutic classes shall be discontinued before Oct. 1, 2017.

If a branded product is preferred in the Single PDL for selected therapeutic classes, the MCO shall consider the generic form non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.